DADC
LGND icon

D.A. Davidson & Co’s Ligand Pharmaceuticals LGND Stock Holding History

D.A. Davidson & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,928
Closed -$386K – 1089
2019
Q1 		$386K Buy
4,928
+2,259
+85% +$171K 0.01% 768
2018
Q4 		$226K Sell
2,669
-1,138
-30% -$121K ﹤0.01% 923
2018
Q3 		$652K Sell
3,807
-459
-11% -$69.2K 0.01% 624
2018
Q2 		$551K Sell
4,266
-1
-0% -$112 0.01% 668
2018
Q1 		$440K Buy
4,267
+24
+0.6% +$2.37K 0.01% 734
2017
Q4 		$362K Sell
4,243
-133
-3% -$11.5K 0.01% 772
2017
Q3 		$371K Buy
4,376
+2,569
+142% +$203K 0.01% 767
2017
Q2 		$136K Sell
1,807
-41
-2% -$2.87K ﹤0.01% 1133
2017
Q1 		$122K Sell
1,848
-829
-31% -$54.5K ﹤0.01% 1159
2016
Q4 		$168K Sell
2,677
-83
-3% -$5.24K ﹤0.01% 1076
2016
Q3 		$174K Buy
2,760
+64
+2% +$4.7K ﹤0.01% 998
2016
Q2 		$200K Buy
+2,696
New +$200K 0.01% 840

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

D.A. Davidson & Co's LGND Position: Q2 2019 in Review

D.A. Davidson & Co sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 4,928 shares — an estimated $386K sold.

D.A. Davidson & Co first reported a position in LGND in Q2 2016 and held it in 12 quarters. The position peaked at $652K in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

  • D.A. Davidson & Co reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • D.A. Davidson & Co sold 4,928 Ligand Pharmaceuticals shares in Q2 2019, an estimated $386K.
  • D.A. Davidson & Co first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 12 quarters.
  • D.A. Davidson & Co's Ligand Pharmaceuticals position peaked at $652K in Q3 2018.
  • 305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on D.A. Davidson & Co's 13F filing for Q2 2019, filed 13 Aug 2019.